GLP-1 Pregnancy Evidence Evolves From Anecdote to ACOG Guidance
In a roundup, Becker's Hospital Review traces how evidence on GLP-1 drugs and pregnancy evolved from 2023 social media speculation about an "Ozempic baby boom" to formal clinical guidance by late 2026. Key milestones include a 2024 study finding no increased malformation risk in diabetic women taking GLP-1s around conception, an August 2026 international panel review of 34 studies finding no increased congenital anomaly risk but only partial direct evidence across clinical questions, and an October 2026 ACOG advisory recommending against use during pregnancy and stopping the drugs one to two months before conception. ACOG also said patients may resume injectable GLP-1s while breastfeeding with infant monitoring but should avoid oral versions. The guidance affects prescribers, OB-GYNs, and patients using GLP-1s for diabetes, obesity, or off-label fertility-related reasons.